Castration-Resistant Prostatic Cancer Clinical Trial
Official title:
Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials. In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as: - Hematology blood tests - Clinical Chemistry blood tests - Testosterone/Prostate Antigen levels blood test - Vital signs - Imaging - ECG
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04116164 -
Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
Early Phase 1 | |
| Not yet recruiting |
NCT04126915 -
Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
|
||
| Recruiting |
NCT04104607 -
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma
|
Phase 1 | |
| Recruiting |
NCT03016741 -
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
|
Phase 4 | |
| Completed |
NCT02398526 -
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
|
||
| Active, not recruiting |
NCT05551117 -
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04404140 -
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
|
Phase 1 | |
| Recruiting |
NCT02998567 -
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
|
Phase 1 | |
| Active, not recruiting |
NCT03748641 -
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05293496 -
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
|
Phase 1 |